Akari Therapeutics receives Nasdaq delisting notice; plans to appeal

Akari Therapeutics Plc

Received Nasdaq delisting determination on Oct 1, 2024 for non-compliance with $2.5M stockholders' equity requirement.
Company intends to request hearing by Oct 8, 2024; hearing automatically stays suspension.
Expects to regain compliance upon closing pending merger with Peak Bio, Inc.
No assurance of success; shares at risk of suspension if appeal fails.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.